CME/CE from MPR


MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for myCME.com. See below for a list of each quarter's courses. Click here to visit MPR's website.




Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits
Clinical Review

New Drug Review from MPR (October 2013)

1.00 Credits
HM 



Archived CME/CE Courses

HM 


MPR Drug News


Novel HCV Infection Combo Tx Gets FDA OK

The Food and Drug Administration (FDA) has approved Viekira Pak (ombitasvir, paritaprevir, ritonavir with dasabuvir tablets; AbbVie) for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infection, including cirrhosis.

First-in-Class Drug for Advanced Ovarian Cancer Approved

The Food and Drug Administration (FDA) has granted accelerated approval for Lynparza (olaparib; AstraZeneca) for the treatment of advanced ovarian cancer associated with defective BRCA genes.

FDA Designates Translara Orphan Drug for Mucopolysaccharidosis I

The Food and Drug Administration (FDA) has granted Orphan Drug designation to Translarna (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I).

Malignant Pleural Mesothelioma Therapy Designated Orphan Drug Status

The Food and Drug Administration (FDA) has granted Orphan Drug designation to ADI-PEG 20 (pegylated arginine deiminase; Polaris) for the treatment of malignant pleural mesothelioma (MPM).

First Waterless Nasal Spray Approved for Children

Teva announced that the Food and Drug Administration (FDA) has approved QNASL (beclomethasone dipropionate) 40mcg for the treatment of nasal symptoms associated with allergic rhinitis in children 4-11 years old.